Equities

Mankind Pharma Ltd

MANKIND:NSI

Mankind Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,554.00
  • Today's Change-6.10 / -0.24%
  • Shares traded116.79k
  • 1 Year change+32.15%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Mankind Pharma Ltd grew revenues 18.12% from 87.49bn to 103.35bn while net income improved 49.23% from 12.82bn to 19.13bn.
Gross margin70.48%
Net profit margin19.41%
Operating margin20.89%
Return on assets17.05%
Return on equity22.27%
Return on investment21.79%
More ▼

Cash flow in INRView more

In 2024, Mankind Pharma Ltd increased its cash reserves by 25.32%, or 771.87m. The company earned 21.52bn from its operations for a Cash Flow Margin of 20.83%. In addition the company generated 52.66m cash from financing while 20.82bn was spent on investing.
Cash flow per share63.95
Price/Cash flow per share39.95
Book value per share263.69
Tangible book value per share222.76
More ▼

Balance sheet in INRView more

Mankind Pharma Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 4.28%.
Current ratio2.95
Quick ratio2.37
Total debt/total equity0.0456
Total debt/total capital0.0428
More ▼

Growth rates in INR

Year on year, growth in earnings per share excluding extraordinary items increased 49.01%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
35.63
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.